- Home
- NMS vs DTIL Comparison
NMS vs DTIL Comparison
Compare NMS & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- DTIL
- Stock Information
- Founded
- NMS 1993
- DTIL 2006
- Country
- NMS United States
- DTIL United States
- Employees
- NMS N/A
- DTIL N/A
- Industry
- NMS Finance Companies
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- NMS Finance
- DTIL Health Care
- Exchange
- NMS Nasdaq
- DTIL Nasdaq
- Market Cap
- NMS 67.0M
- DTIL 55.3M
- IPO Year
- NMS N/A
- DTIL 2019
- Fundamental
- Price
- NMS $11.27
- DTIL $4.96
- Analyst Decision
- NMS
- DTIL Strong Buy
- Analyst Count
- NMS 0
- DTIL 2
- Target Price
- NMS N/A
- DTIL $47.00
- AVG Volume (30 Days)
- NMS 12.0K
- DTIL 84.3K
- Earning Date
- NMS 01-01-0001
- DTIL 08-07-2025
- Dividend Yield
- NMS 4.11%
- DTIL N/A
- EPS Growth
- NMS N/A
- DTIL N/A
- EPS
- NMS N/A
- DTIL N/A
- Revenue
- NMS N/A
- DTIL $1,261,000.00
- Revenue This Year
- NMS N/A
- DTIL N/A
- Revenue Next Year
- NMS N/A
- DTIL $135.19
- P/E Ratio
- NMS N/A
- DTIL N/A
- Revenue Growth
- NMS N/A
- DTIL N/A
- 52 Week Low
- NMS $9.21
- DTIL $3.61
- 52 Week High
- NMS $12.18
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- NMS 47.82
- DTIL 56.59
- Support Level
- NMS $11.19
- DTIL $4.55
- Resistance Level
- NMS $11.45
- DTIL $4.99
- Average True Range (ATR)
- NMS 0.11
- DTIL 0.32
- MACD
- NMS -0.01
- DTIL 0.02
- Stochastic Oscillator
- NMS 32.08
- DTIL 81.11
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.